Technical Analysis for ANRO - Alto Neuroscience, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.35% | |
| 20 DMA Resistance | Bearish | -0.14% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.14% | |
| MACD Bullish Signal Line Cross | Bullish | -0.14% | |
| Up 3 Days in a Row | Strength | -0.14% |
| Alert | Time |
|---|---|
| Possible NR7 | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
| 20 DMA Support | about 21 hours ago |
| Down 1% | about 22 hours ago |
| Fell Below 20 DMA | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Schizophrenia Biomarkers Depression Neurophysiology Post Traumatic Stress Disorder Electroencephalography Neurocognition Ptsd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Schizophrenia Biomarkers Depression Neurophysiology Post Traumatic Stress Disorder Electroencephalography Neurocognition Ptsd
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.0 |
| 52 Week Low | 12.7798 |
| Average Volume | 200,501 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 14.63 |
| 20-Day Moving Average | 14.03 |
| 10-Day Moving Average | 13.77 |
| Average True Range | 0.93 |
| RSI (14) | 47.37 |
| ADX | 12.18 |
| +DI | 15.02 |
| -DI | 16.16 |
| Chandelier Exit (Long, 3 ATRs) | 15.52 |
| Chandelier Exit (Short, 3 ATRs) | 15.57 |
| Upper Bollinger Bands | 14.84 |
| Lower Bollinger Band | 13.21 |
| Percent B (%b) | 0.59 |
| BandWidth | 11.64 |
| MACD Line | -0.33 |
| MACD Signal Line | -0.41 |
| MACD Histogram | 0.0799 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.54 | ||||
| Resistance 3 (R3) | 14.50 | 14.34 | 14.48 | ||
| Resistance 2 (R2) | 14.34 | 14.25 | 14.36 | 14.46 | |
| Resistance 1 (R1) | 14.26 | 14.19 | 14.30 | 14.30 | 14.44 |
| Pivot Point | 14.10 | 14.10 | 14.12 | 14.12 | 14.10 |
| Support 1 (S1) | 14.02 | 14.01 | 14.06 | 14.06 | 13.92 |
| Support 2 (S2) | 13.86 | 13.95 | 13.88 | 13.90 | |
| Support 3 (S3) | 13.78 | 13.86 | 13.88 | ||
| Support 4 (S4) | 13.82 |
